Uncomplicated ABRS with non-type 1 penicillin hypersensitivity — when first-line therapy has not resolved symptoms
This protocol applies when a patient with uncomplicated acute bacterial rhinosinusitis (ABRS) and known non-type 1 penicillin hypersensitivity has already received first-line antibiotic therapy without adequate symptom resolution.
Clinical scenario
Uncomplicated acute bacterial rhinosinusitis in a patient with non-type 1 penicillin hypersensitivity. ABRS is diagnosed when signs and symptoms — purulent nasal drainage with nasal obstruction, facial pain-pressure-fullness, or both — persist without improvement for at least 10 days from onset, or worsen within 10 days after an initial improvement (double worsening).
Previous treatment — failure condition
The first-line regimen for this patient population — either doxycycline or a third-generation oral cephalosporin, with or without clindamycin — is expected to produce measurable symptom improvement within 3 to 5 days of initiation. When signs and symptoms of ABRS do not improve within that window, escalation to a next-line regimen is indicated.
Next-line approach (partial)
The next-line regimen involves a respiratory fluoroquinolone — a drug class reserved specifically for patients in whom no alternative treatment options remain. Selection, dosing, and duration are detailed in the full structured protocol.
References
DOI: 10.1002/ohn.1344
- A clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis (purulent nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without evidence of improvement for at least 10 days beyond the onset of upper respiratory symptoms, or (b) symptoms or signs of acute rhinosinusitis worsen within 10 days after an initial improvement (double worsening).
- For patients with non-type 1 penicillin hypersensitivity, either doxycycline or a third-generation oral cephalosporin (cefixime 400 mg PO od or cefpodoxime 200 mg PO bid) with or without clindamycin (450 mg PO tid) is recommended.
- Respiratory fluoroquinolone (levofloxacin 500 mg or 750 mg PO od or moxifloxacin 400 mg PO od) is another alternative, but this antibiotic regimen should be reserved for those who have no alternative treatment options for reasons noted above.
View source ↗